| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2019: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2016: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to establish a system for identifying and testing genotype-oriented targeted drugs for pancreatobiliary cancers by combining exome sequencing and organoid culture of primary tumors. Tumor cells isolated from resected tumors were subjected to organoid cultures. Exome sequencing was performed on the primary tumors. Genotype-oriented candidate targeted drugs were identified from the exome sequencing and their efficacies were tested in the organoids. Organoid cultures were succeeded in 30 of 54 (55.6%) cases. Exome sequencing revealed a variety of somatic mutations. Some of the aberrations were candidates for targeted therapies. Integrin-linked kinase (ILK) was a novel candidate target, and an ILK inhibitor was confirmed to suppress proliferation of patient-derived organoids. By combining exome sequencing and organoid culture, our model enabled to identify genotype-oriented targets for personalized medicine and to test efficacies of candidate targeted drugs in the organoids.
|
